Granted Patent B2

US 12,528,855 · App. 17/413,654 · Granted Jan 20, 2026

Inventors: Amit Aggarwal (Indianapolis, IN); Katja Fiedler (Tübingen, DE); Ulrike Gnad-Vogt (Tübingen, DE); Regina Heidenreich (Tübingen, DE); Mythili Koneru (Indianapolis, IN); Gregory D. Plowman (Indianapolis, IN)

Assignee: CureVac SE

C07K14/70539A61K47/18A61K47/183A61K47/24A61K47/28C07K14/70521C12N9/14C12N15/625C12Y306/05002A61K38/00

Abstract

Claims (20)

1 . An mRNA molecule comprising an mRNA sequence encoding an amino acid sequence comprising a CTLA4 signal peptide, a KRAS variant peptide, PADRE-derived T helper epitope sequence, and a CTLA4 transmembrane domain.

2 . The mRNA molecule according to claim 1 , wherein the KRAS variant peptide comprises the KRAS G12C variant amino acid residue, the KRAS G12D variant amino acid residue, the KRAS G12V variant amino acid residue, the KRAS G12R variant amino acid residue, or the KRAS G13D variant amino acid residue.

3 . The mRNA molecule according to claim 1 , further comprising an alpha-globin 3′ UTR element.

4 . The mRNA molecule according to claim 3 , wherein the mRNA encoding a KRAS variant peptide is located 5′ of the alpha-globin 3′ UTR element.

5 . The mRNA molecule according to claim 1 , wherein the KRAS variant peptide comprises the sequence of SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11 or SEQ ID NO: 12.

6 . The mRNA molecule according to claim 1 , wherein the molecule comprises SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56 or SEQ ID NO: 57.

7 . The mRNA molecule according to claim 1 , wherein the mRNA is set forth in SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66 or SEQ ID NO: 67.

8 . The mRNA molecule according to claim 1 , wherein the mRNA molecule is set forth in SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61 or SEQ ID NO: 62.

9 . The mRNA molecule according to claim 1 , wherein the mRNA molecule encodes a KRAS variant peptide set forth in SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51 or SEQ ID NO: 52.

10 . A pharmaceutical composition comprising the mRNA molecule of claim 1 , and one or more pharmaceutically acceptable carriers or excipients.

11 . The pharmaceutical composition of claim 10 , wherein the composition comprises 1, 2, 3, 4 or 5 different mRNA molecules, wherein each mRNA molecule encodes a different KRAS variant peptide.

12 . The pharmaceutical composition of claim 11 , further comprising a cationic lipid, a sterol, a neutral lipid, and a PEG lipid.

13 . The pharmaceutical composition according to claim 12 , wherein the PEG lipid is of the formula:

wherein R 8 and R 9 are each independently a straight or branched, saturated or unsaturated alkyl chain containing from 10 to 30 carbon atoms, wherein the alkyl chain is optionally interrupted by one or more ester bonds; and w has a mean value ranging from 30 to 60.

14 . The pharmaceutical composition according to claim 12 , wherein the neutral lipid is distearoylphophocholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoyl-phosphoethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1-trans PE, 1-stearioyl-2-oleoylphosphatidyethanol amine (SOPE), or 1,2-dielaidoyl-sn-glycero-3-phophoethanolamine (transDOPE).

15 . The pharmaceutical composition according to claim 12 , wherein the sterol is cholesterol.

16 . The pharmaceutical composition according to claim 12 , wherein the PEG lipid is 2-mPEG2000-n,n ditetradecylacetamide, the neutral lipid is 1,2-distearoyl-sn-glycero-3-phosphocholine, and the sterol is cholesterol.

17 . The pharmaceutical composition according to claim 12 , comprising a molar ratio of about 20-60% cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-lipid.

18 . A kit comprising the mRNA of claim 1 and optionally instructions with information on the administration and dosage of the mRNA molecule.

19 . A method of treating cancer, comprising administering to a patient in need thereof an effective amount of the mRNA molecule of claim 1 , wherein the cancer is a solid tumor cancer that is bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, gastric cancer, testicular cancer, thyroid cancer, or uterine cancer.

Assignments (9)

Continuity (3)

References Cited (269)